LNP023

selective factor B serine protease inhibitor

orally available, retinal barrier penetrant

J. Med. Chem., Feb. 19, 2020

Novartis (NIBR), Cambridge, MA

February’s molecule, the Novartis factor B inhibitor LNP023, targets the serine protease factor B (FB), a key node in the complement system. The complement part of the innate immune system is…


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.